Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Hyperactivation of MAPK Signaling Is Deleterious to RAS/RAF-mutant Melanoma.

Leung GP, Feng T, Sigoillot FD, Geyer FC, Shirley MD, Ruddy DA, Rakiec DP, Freeman AK, Engelman JA, Jaskelioff M, Stuart DD.

Mol Cancer Res. 2019 Jan;17(1):199-211. doi: 10.1158/1541-7786.MCR-18-0327. Epub 2018 Sep 10.

PMID:
30201825
2.

Utilizing murine inducible telomerase alleles in the studies of tissue degeneration/regeneration and cancer.

Shingu T, Jaskelioff M, Yuan L, Ding Z, Protopopov A, Kost-Alimova M, Hu J.

J Vis Exp. 2015 Apr 13;(98). doi: 10.3791/52599.

3.

Functional epigenetics approach identifies BRM/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers.

Hoffman GR, Rahal R, Buxton F, Xiang K, McAllister G, Frias E, Bagdasarian L, Huber J, Lindeman A, Chen D, Romero R, Ramadan N, Phadke T, Haas K, Jaskelioff M, Wilson BG, Meyer MJ, Saenz-Vash V, Zhai H, Myer VE, Porter JA, Keen N, McLaughlin ME, Mickanin C, Roberts CW, Stegmeier F, Jagani Z.

Proc Natl Acad Sci U S A. 2014 Feb 25;111(8):3128-33. doi: 10.1073/pnas.1316793111. Epub 2014 Feb 11.

4.

Telomerase reactivation following telomere dysfunction yields murine prostate tumors with bone metastases.

Ding Z, Wu CJ, Jaskelioff M, Ivanova E, Kost-Alimova M, Protopopov A, Chu GC, Wang G, Lu X, Labrot ES, Hu J, Wang W, Xiao Y, Zhang H, Zhang J, Zhang J, Gan B, Perry SR, Jiang S, Li L, Horner JW, Wang YA, Chin L, DePinho RA.

Cell. 2012 Mar 2;148(5):896-907. doi: 10.1016/j.cell.2012.01.039. Epub 2012 Feb 16.

5.

Antitelomerase therapy provokes ALT and mitochondrial adaptive mechanisms in cancer.

Hu J, Hwang SS, Liesa M, Gan B, Sahin E, Jaskelioff M, Ding Z, Ying H, Boutin AT, Zhang H, Johnson S, Ivanova E, Kost-Alimova M, Protopopov A, Wang YA, Shirihai OS, Chin L, DePinho RA.

Cell. 2012 Feb 17;148(4):651-63. doi: 10.1016/j.cell.2011.12.028.

6.

Proinvasion metastasis drivers in early-stage melanoma are oncogenes.

Scott KL, Nogueira C, Heffernan TP, van Doorn R, Dhakal S, Hanna JA, Min C, Jaskelioff M, Xiao Y, Wu CJ, Cameron LA, Perry SR, Zeid R, Feinberg T, Kim M, Vande Woude G, Granter SR, Bosenberg M, Chu GC, DePinho RA, Rimm DL, Chin L.

Cancer Cell. 2011 Jul 12;20(1):92-103. doi: 10.1016/j.ccr.2011.05.025.

7.

Telomere dysfunction induces metabolic and mitochondrial compromise.

Sahin E, Colla S, Liesa M, Moslehi J, Müller FL, Guo M, Cooper M, Kotton D, Fabian AJ, Walkey C, Maser RS, Tonon G, Foerster F, Xiong R, Wang YA, Shukla SA, Jaskelioff M, Martin ES, Heffernan TP, Protopopov A, Ivanova E, Mahoney JE, Kost-Alimova M, Perry SR, Bronson R, Liao R, Mulligan R, Shirihai OS, Chin L, DePinho RA.

Nature. 2011 Feb 17;470(7334):359-65. doi: 10.1038/nature09787. Epub 2011 Feb 9. Erratum in: Nature. 2011 Jul 14;475(7355):254.

8.

Telomerase reactivation reverses tissue degeneration in aged telomerase-deficient mice.

Jaskelioff M, Muller FL, Paik JH, Thomas E, Jiang S, Adams AC, Sahin E, Kost-Alimova M, Protopopov A, Cadiñanos J, Horner JW, Maratos-Flier E, Depinho RA.

Nature. 2011 Jan 6;469(7328):102-6. doi: 10.1038/nature09603. Epub 2010 Nov 28.

9.

Telomerase deficiency and telomere dysfunction inhibit mammary tumors induced by polyomavirus middle T oncogene.

Jaskelioff M, Song W, Xia J, Liu C, Kramer J, Koido S, Gendler SJ, Calderwood SK, Gong J.

Oncogene. 2009 Dec 3;28(48):4225-36. doi: 10.1038/onc.2009.268. Epub 2009 Sep 7.

PMID:
19734944
10.

Chromatin and transcription: histones continue to make their marks.

Jaskelioff M, Peterson CL.

Nat Cell Biol. 2003 May;5(5):395-9. No abstract available.

PMID:
12724776
11.

Rad54p is a chromatin remodeling enzyme required for heteroduplex DNA joint formation with chromatin.

Jaskelioff M, Van Komen S, Krebs JE, Sung P, Peterson CL.

J Biol Chem. 2003 Mar 14;278(11):9212-8. Epub 2003 Jan 3.

12.

SWI-SNF-mediated nucleosome remodeling: role of histone octamer mobility in the persistence of the remodeled state.

Jaskelioff M, Gavin IM, Peterson CL, Logie C.

Mol Cell Biol. 2000 May;20(9):3058-68.

Supplemental Content

Loading ...
Support Center